title: [The efficacy of indisetron hydrochloride for the management of chemotherapy-induced nausea and vomiting for lung cancer].
abstract: We set out to determine the efficacy of indisetron hydrochloride for the management of chemotherapy-induced nausea and vomiting including carboplatin for lung cancer. Indisetron hydrochloride was given orally to 32 patients (indisetron group), and intravenous 5-HT3 receptor antagonists were given to 24 patients (control group). The number of patients with nausea or vomiting occurring within 24 hours and 24 to 72 hours after chemotherapy was measured. The complete inhibition of the vomiting within 24 hours after chemotherapy was 100% in the indisetron group and 95.8% in the control group. Twenty-four to 72 hours after chemotherapy, the complete inhibition of vomiting rate was 97.1% and 95.8%, respectively. In addition, the complete inhibition of nausea rate within 24 hours after chemotherapy was 87.5% in the indisetron group and that was 95.8% in the control group. The complete inhibition of nausea rate 24 to 72 hours after chemotherapy was 56.3% and 70.8%, respectively. No serious adverse events were observed. The comparison of the efficacy between the indisetron group and control groups did not reach statistical significance (p> 0.05). These findings suggest that prophylactic administration of indisetron hydrochloride is useful for the inhibition of acute and delayed nausea and vomiting caused by chemotherapy in lung cancer patients.
authors.affiliation: First Dept. of Medicine, Tokyo Women's Medical University, School of Medicine.
authors.forename: Eiichi
authors.initials: E
authors.lastname: Iritani
authors.forename: Kazuo
authors.initials: K
authors.lastname: Isono
authors.forename: Takehiro
authors.initials: T
authors.lastname: Izumo
authors.forename: Naoko
authors.initials: N
authors.lastname: Takeda
authors.forename: Toshinori
authors.initials: T
authors.lastname: Kanemura
authors.forename: Jun
authors.initials: J
authors.lastname: Tamaoki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nagai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D012702:Serotonin Antagonists / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D011720:Pyrazoles; D012702:Serotonin Antagonists; C500220:indisetron hydrochloride; D016190:Carboplatin